Last updated 13 days ago
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
723 patients around the world
Available in Argentina, United States
Pfizer
1Research sites
723Patients around the world
This study is for people with
Migraine
Menstrual Migraine
Requirements for the patient
To 45 Years
Female
Medical requirements
- Participant has regular menstrual cycles ≥24 days and ≤34 days.A minimum 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition.A history of menstrual migraine attacks of at least 3 months.Participant reported history of experiencing at least 1 migraine attack during the perimenstrual period in at least 2 out of 3 menstrual cycles immediately prior to screening.If the participant is receiving a permitted background continuous prophylactic migraine medication, the medication dose must be stable for at least 3 months prior to the Screening visit and, the dose is not expected to change during the course of the study.
- Greater than 6 migraine days per month that are outside of the perimenstrual period in the 3 months prior to Screening.A diagnosis of chronic migraine or a history of more than 14 headache days per month on average, in the 3 months prior to Screening.History of retinal migraine, basilar migraine or hemiplegic migraine.Current diagnosis of schizophrenia, bipolar, or borderline personality disorder.Other pain syndromes (eg, fibromyalgia, complex regional pain syndrome), or significant neurological disorders (other than migraine), or other medical conditions (including endocrine and gynecological eg, severe dysmenorrhea).
Sites
Instituto de Diagnóstico e Investigaciones Metabólicas - IDIM - sede centro - CABA
SponsorPfizer
Study typeInterventional
Conditions
Menstrual Migraine
Requirements
To 45 YearsFemale
Unique study IDclinicaltrials.gov
NCT06641466
